Gastrointestinal Devices Global Market Report 2023 – By Product Type (GI Videoscopes, Biopsy Devices, Endoscopic Retrograde Cholangiopancreatography Devices (ERCP), Capsule Endoscopy, Endoscopic Ultrasound, Endoscopic Mucosal Resection (EMR), Hemostasis Devices, Other Product Types), By End Users (Hospitals, Clinics & Dialysis Centers, Ambulatory Surgical Center), By Sales Channel (Online Retailing, Medical Stores & Brand Outlet) – Market Size, Trends, And Global Forecast 2023-2032

Endoscopy devices and equipment are used to examine the interiors of organs, and the cavities of the body. These devices enable doctors to view the digestive tract on a screen and aid in the diagnosis of medical conditions. The main products of endoscopy devices and equipment are endoscopes, endoscopy operative devices, and endoscopy visualization systems. The endoscope is a lighted optical instrument that is used to get a deep look inside the body. An endoscope, which is rigid or flexible, is used to examine organs, like the throat or esophagus. The various applications involved are bronchoscopy, arthroscopy, laparoscopy, urology endoscopy, neuroendoscopy, gastrointestinal endoscopy, obstetrics/gynecology endoscopy, ENT endoscopy, and others that are used by various end-users such as hospitals, clinics, and others. The global endoscopy devices and equipment market is segmented - 1) By Product: Endoscope, Endoscopy Operative Devices , Endoscopy Visualization Systems 2) By Application: Bronchoscopy, Arthroscopy, Laparoscopy, Urology endoscopy, Neuroendoscopy, Gastrointestinal endoscopy, Obstetrics/gynecology endoscopy, ENT endoscopy, Other Applications 3) By End-User: Hospitals, Clinics, Other End Users The global endoscopy devices and equipment market size will grow from $7.9 billion in 2022 to $8.5 billion in 2023 at a compound annual growth rate (CAGR) of 7.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the endoscopy devices and equipment is expected to grow to $10.94 billion in 2027 at a CAGR of 6.5%. The rise in incidence and prevalence rates of gastrointestinal (GI) diseases is driving the endoscopy devices and equipment market. The increasing incidence of gastrointestinal diseases such as colorectal cancer, gastroesophageal reflux disease, ulcerative colitis (UC), inflammatory bowel disease (IBD), and Crohn's disease (CD) are supporting the endoscopy devices and equipment market. The endoscopy devices are used in performing non-invasive or minimally invasive surgical procedures to treat life-threatening diseases. The Asian countries have the highest prevalence rates of gastrointestinal diseases such as cancer. In Korea, with every 39.6 persons per 100,000 suffering from cancer, Mongolia with 33.1 per 100,000, and Japan with 27.5 per 100,000 ranked as 1, 2, and 3 respectively. Due to the rising prevalence of GI diseases, developing countries are experiencing high demand for minimally invasive surgical procedures, increasing the demand for endoscopy devices and equipment market growth. Major players in the endoscopy devices and equipment market are Olympus Corporation, Fujifilm, Boston Scientific Corporation, Conmed Corporation, Stryker Corporation, Smith & Nephew PLC., KARL STORZ GmbH & Co. KG, Hoya Corporation, Johnson & Johnson, and Ethicon. Regulatory changes are likely to increase costs related to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to Dr. Fazal data 2020, 92% of working at an enterprise (over 1,000 employees) expect GDPR compliance to cost their business over $50,000. About 44% of the companies spend more than $50,000 and about 10% spend over a million dollars. according to a report by Ernst and Young (EY), Fortune 500 companies are spending $7.8 billion to comply with GDPR. The GDPR is an EU law on the data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k) by over 55% over the last decade. The potential loss of revenue due to delay in product release and additional costs incurred due to stringent approval processes puts strain on investments relating to new product development, thereby affecting the growth of the market. Companies in the endoscopy devices and equipment market are increasingly developing endoscopy robotic systems as they are more flexible, effective than conventional endoscopy devices. These robotic endoscopy devices help in eliminating difficulties in therapeutic endoscopy, expanding endoscopy’s vision and reach, reducing labor intensity, improving communication, reach, vision, control, and the ability to perform an endoscopy. These devices are used in gastrointestinal surgeries, urology/gynecology surgeries, ENT surgeries, cardiovascular surgeries, neuro/spinal surgeries, laparoscopy surgeries, and arthroscopy surgical applications. In 2021, Fujifilm partnered with SMART Medical Systems for developing a next-generation solution for colon endoscopy, the G-EYE 700-series endoscope system. The unique innovation offers exceptional visualization capabilities and outstanding quality of diagnostic images. Medicines and Healthcare products Regulatory Agency(MRHA), a regulatory body for medical devices of the UK, is a regulatory body governing drug and device alerts, drug safety updates, blood regulation, and safety, marketing authorizations and licensing guidance, medical devices regulation, and safety and many other activities. According to safety guidelines by MRHA, the medical device manufacturing companies in the industry recall their medical devices if any problem or defect is detected. For instance, in April 2022, KARL STORZ, a German endoscopy device company, issued urgent medical device recall notice for certain KARL STORZ flexible endoscopes after it detected issues in product description and instructions for use and potential risk of injury during the use of the device. North America was the largest region in the global endoscopy devices and equipment market in 2022. Asia-Pacific was the second largest market in endoscopy devices and equipment market analysis. The regions covered in the global endoscopy devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the vision care devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The endoscopy devices and equipment market consist of sales of instruments such as biopsy forceps, trocar sleeves, tissue scissors and cutters, burs, cleaning brushes, tube sets (inflow and outflow), tissue staplers, ligation devices, and suturing systems. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The endoscopy devices and equipment market research report is one of a series of new reports from The Business Research Company that provides endoscopy devices and equipment market statistics, including endoscopy devices and equipment industry global market size, regional shares, competitors with a endoscopy devices and equipment market share, detailed endoscopy devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the endoscopy devices and equipment industry. This endoscopy devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antacids drugs refer to the drugs that are used to neutralize stomach acid, and treat acid reflux, heartburn, and indigestion. Antacids are medications that counteract (neutralise) your stomach's acid to ease heartburn and indigestion. They are available without a prescription from pharmacies and stores and come in liquid or chewable tablet form. It includes drug classes such as proton pump inhibitors, H2 antagonists, surgical simulators, and acid neutralizers in the form of tablets, liquid, or powder. The main classes of antacids are proton pump inhibitors, H2 antagonists, acid neutralizers, and pro-motility agents. Proton-pump inhibitors are a type of drug that reduces stomach acid production significantly and for a long time. They accomplish this by blocking the H+/K+ ATPase proton pump in the stomach in an irreversible manner. The different types of formulations include tablets, liquids, powders, and others and are distributed through various channels such as hospital pharmacies, retail pharmacies, and others. The global antacids market is segmented – 1) Drug Class: Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Pro-Motility Agents 2) Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels 3) By Formulation Type: Tablet, Liquid, Powder, Other Formulation Types The global antacids market size will grow from $9.19 billion in 2022 to $9.56 billion in 2023 at a compound annual growth rate (CAGR) of 4.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global antacids is expected to grow to $10.65 billion in 2027 at a CAGR of 2.7%. Poor lifestyle choices resulting in a higher prevalence of acidity are an important driver for the growth of the antacids market. Poor lifestyle choices involve deskbound jobs, poor quality of sleep, and irregular dietary habits, which result in an increase in the acidity level of the stomach and lead to gastroesophageal reflux disease. According to the American College of Gastroenterology, around 60 million Americans suffer from gastroesophageal reflux disease. This drives the demand for antacids. Major players in the antacids market are GlaxoSmithKline PLC., Pfizer Inc., Bayer AG, Dr. Reddy's Laboratories Ltd., and AstraZeneca PLC, Boehringer Ingelheim GmbH, Sun Pharmaceuticals Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, and WellSpring Pharm. The side effects related to antacids are a major restraint for the antacids market. Some of the common side effects of antacids include dose-dependent rebound hyperacidity and milk-alkali syndrome. Antacids containing aluminum hydroxide may also cause side effects such as constipation, aluminum-intoxication, osteomalacia, and hypophosphatemia. In addition, antacids when consumed with other acidic drugs might lead to absorption of both the drugs resulting in reduced efficiency of both the drugs. Mouth-melting antacid is an emerging trend in the antacid market. Antacids were available in tablet, liquid, and powder form until now, however, researchers have now come up with mouth-melting antacids which are made up of micro-mouth melting granules that easily melt in the mouth. These granules present in the antacids act in the form of effervescent. An example of a mouth-melting instant relief antacid is Sunpharma's 'Pepmelt', which integrates the effects of herbal constituents present in it with the contemporary mouth-melting technology. The manufacturers of antacids in the USA need to comply with CFR - Code of Federal Regulations Title 21 laid down by the FDA. According to these regulations, an over-the-counter (OTC) antacid product in a form suitable for oral administration is recognized as safe and effective only if it meets the conditions related to active ingredients established by the regulatory body. North America was the largest region in the antacids market in 2022. The Middle East is expected to be the fastest-growing region in the global antacids market share. The regions covered in the global antacids market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antacids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The antacids market consists of sales of Alka Seltzer, Maalox, Mylanta, Rolaids, Tums, and Pepto-Bismol. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The antacids market research report is one of a series of new reports from The Business Research Company that provides antacids market statistics, including antacids industry global market size, regional shares, competitors with an antacids market share, detailed antacids market segments, market trends, and opportunities, and any further data you may need to thrive in the antacids industry. This antacids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical drug refers to a substance created to treat, prevent, or cure an illness or other condition, or to lessen its symptoms. To list the most popular methods, drugs can be consumed orally, through a skin patch, by injection, or through an inhaler. Other vital medications made from natural materials include vaccinations, steroid hormones, human blood-plasma fractions, and antibiotics. The main types of pharmaceutical drugs are cardiovascular drugs, dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorders drugs, musculoskeletal disorders drugs, central nervous system drugs, oncology drugs, ophthalmology drugs, and respiratory diseases drugs. Cardiovascular drugs are used to treat medical conditions associated with the heart or the circulatory system (blood vessels), such as arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and stroke. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global pharmaceutical drugs market is segmented - 1) By Type: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels 3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs Subsegments Covered: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Drugs), Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases, Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals, Hormonal Contraceptives, Drugs For Benign Prostatic hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overactive Bladder, Drugs For Infections And Others, Drugs For Hormonal Replacement Therapy, Diuretics, Blood Products, Anemia And Other Blood Disorder Drugs, Antibiotics, Antivirals, Antifungals, Others (Anthelminthic, Antiprotozoal), Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism), Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs, Analgesics, Anti-Parkinson drugs, Anesthetics, Anti-Epileptics, Other CNS drugs, Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma), Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy), Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations The global pharmaceutical drugs market size is expected to grow from $ 1,136.23 billion in 2022 to $1,199.86 billion in 2023 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The market size of global pharmaceutical drugs market is expected to reach $1,848.49 billion in 2027 at a CAGR of 11.4%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. China and India together had about 193.4 million diabetic patients in 2019 and India is expected to have about 101 million diabetic patients by 2030, thereby increasing the need for biologics drugs for diabetic patients. These factors are expected to increase the patient pool globally, thereby driving the growth of pharmaceutical drug market during the forecast period. Major companies in the pharmaceutical drugs market include Bristol-Myers Squibb, Sanofi S.A, Johnson & Johnson, Novartis AG, Bayer AG, Abbott Laboratories, GlaxosmithKline, AstraZenec, Merck & Co and CJ Corp. Interest rates globally are forecasted to rise in most of the developing and developed economies, during the forecast period, this is expected to limit new investments in the market. Most countries across the world are raising interest rates to control inflation and also to limit the flow of capital out of the country. This is likely to affect new investments in terms of expansion, research, and development of new products. For instance, the US interest rates rose to 3.5% by 2021. These factors are expected to hurt the market as borrowing money becomes expensive, thereby affecting the pharmaceuticals market growth. Early Rx-to-OTC switch, or switching the product from prescription to non-prescription status, is a key trend in the dermatology drugs market. Traditionally, the Rx-to-OTC status conversion was generally observed at a phase nearing the patent expiry or after. However, forward-thinking companies are now looking at switching from Rx-to-OTC well in advance of the patent expiry of the drug. This helps the manufacturer to capitalize on the market opportunities for the product. Early Rx-to-OTC switching also provides an additional benefit as a way to recover all the expenses incurred on the product by the company. For example, in 2020, FDA has switched three prescription drugs to OTC including Voltaren for arthritis pain, olopatadine hydrochloride 0.1% and 0.2% (Pataday Twice Daily Relief and Pataday Once Daily Relief) for temporary relief of itchy and red eyes due to pollen, ragweed, and grass. North America was the largest region in the pharmaceutical drugs market share in 2022. Middle East is expected to be the largest growing region in the forecast period. The regions covered in the global pharmaceutical drugs market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceutical drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The pharmaceutical drug market consists of sales of generic drugs, over-the-counter medications, bulk drugs, vaccines, biosimilars, and biologics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The pharmaceutical drug market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical drug market statistics, including pharmaceutical drug industry global market size, regional shares, competitors with a pharmaceutical drug market share, detailed pharmaceutical drug market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical drug industry. This pharmaceutical drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Hospital-acquired infections are acquired during hospital care that is not present before hospital admission. The prevention and control of hospital-acquired infection using various cleaning, sterilization, and disinfection methods refers to hospital-acquired infection control. These infections can be caused by the cross-infection from the surfaces of equipment, the skin of patients, and healthcare staff. Hospital-acquired infection control is used to reduce or eliminate the transmission of illnesses. The main types of products in hospital-acquired infection control are sterilizers, disinfectors, endoscope reprocessors, microbial testing instruments, reagents, consumables, disinfectants, infection prevention and surveillance software, and others. Sterilizers refer to a machine for making things entirely clean and bacteria-free. Sterilizers are used to kill germs on an article's surface or in a fluid in order to prevent disease transmission. The different technologies include phenotypic and genotypic methods and involve several types of diseases such as hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections and other diseases. The various applications include disease testing and drug-resistance testing. The end user involved are hospitals, ICUs, ambulatory surgical, diagnostic centres, nursing homes, maternity centres, and others. The global hospital acquired infection control market is segmented - 1) By Product: Sterilizers, Disinfectors, Endoscope Reprocessors, Microbial Testing Instruments, Consumables, Disinfectants, Infection Prevention And Surveillance Software, Other Products 2) By Technology: Phenotypic Methods, Genotypic Methods 3) By Diseases: Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, Urinary Tract Infection, Other Diseases 4) By Application: Disease Testing, Drug-Resistance Testing 5) By End User: Hospitals, ICUs, Ambulatory Surgical, Diagnostic Centers, Nursing Homes, Maternity Centers, Other End Users The global hospital-acquired infection control market size grew from $31.02 billion in 2022 to $32.09 billion in 2023 at a compound annual growth rate (CAGR) of 3.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the hospital-acquired infection control market is expected to grow to $36.88 billion in 2027 at a CAGR of 3.5%. The surge in COVID-19 cases is expected to propel the growth of the hospital-acquired infection control market going forward. COVID-19 refers to a viral infection that is caused by the SARS-CoV-2 virus. Due to the COVID-19 pandemic, there is an increase in demand for hospital-acquired infection control products and services to focus on personal hygiene and the production of infection control medical supplies. For instance, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, as of 8th August 2022, the global COVID-19 cases reached 581.6 million. Therefore, the surge in COVID-19 cases is driving the growth of the hospital-acquired infection control market. Major players in the hospital-acquired infection control market are Belimed AG, Advanced Sterilization Products Services Inc., 3M Company, Getinge AB, Olympus Corporation, Ecolab Inc., Steris Healthcare PVT Ltd., MMM Group, Contec Inc., Steelco S.P.A., Miele Group, Sotera Health LLC, Matachana Group, and Reckitt Benckiser Group plc. Technological advancements are a key trend gaining popularity in the hospital-acquired infection control market. Major companies operating in the hospital-acquired infection control market are focused on developing new technological solutions to lead the market. For instance, in November 2021, the scientists of University of Pittsburgh School of Medicine and Carnegie Mellon University, used machine learning technology with whole genome sequencing to rapidly detect infectious disease outbreaks in a hospital. Significant outbreaks that might otherwise escape routine infection prevention monitoring are discovered by this method. In June 2021, Steris Corporation, a US-based medical equipment company specializing in sterilization and surgical products acquired Cantel Medical for an undisclosed amount. This acquisition would help Steris to extend product and service offerings as well as global reach. Cantel Medical is a US-based manufacturer of infection prevention products. North America was the largest region in the hospital-acquired infection control market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hospital-acquired infection control report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the hospital-acquired infection control market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The hospital-acquired infection control market includes revenues earned by entities by heat sterilization equipment, low temperature sterilization equipment, radiation sterilization equipment, other sterilization equipment, contract sterilization services, sterilization consumables and accessories, disinfectants, and disinfectors equipment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The hospital-acquired infection control market research report is one of a series of new reports from The Business Research Company that provides hospital-acquired infection control market statistics, including hospital-acquired infection control industry global market size, regional shares, competitors with a hospital-acquired infection control market share, detailed hospital-acquired infection control market segments, market trends and opportunities, and any further data you may need to thrive in the hospital-acquired infection control industry. This hospital-acquired infection control market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Medical equipment are devices that can be instrument, apparatus or machine that can be used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting or modifying the structure or function of the body for health purpose. The main types of medical equipment are in-vitro diagnostics, dental equipment and supplies, ophthalmic devices, diagnostic imaging equipment, cardiovascular devices, hospital supplies, surgical equipment, orthopedic devices, patient monitoring devices, diabetes care devices, nephrology and urology devices, ENT devices, anesthesia and respiratory devices, neurology devices, and wound care devices. In-vitro diagnostics are tests done on samples like blood or tissue that is taken from the human body. In-vitro diagnostics will detect diseases or other conditions and are used to monitor a person’s overall health to cure, treat, or prevent diseases. The type of expenditure involved is public and private. The various product are instruments/equipment and disposables. The various end users involved are hospitals and clinics, homecare, diagnostics centres, and others. The global medical equipment market is segmented - 1) By Type: In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices 2) By Type of Expenditure: Public, Private 3) By Product: Instruments/Equipment, Disposables 4) By End User: Hospitals And Clinics, Homecare, Diagnostics Centers, Other End Users Subsegments Covered: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment, Therapeutic Dental Equipment, General Dental Devices And Equipment, Dental Diagnostic Imaging Devices And Equipment, Dental Surgical Devices And Equipment, Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment, X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment, Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment, Disposable Hospital Supplies, Sterilization Equipment And Disinfectants, Mobility Aids And Transportation Equipment, Operating Room Equipment, Surgical Sutures And Staples, Handheld Surgical Devices And Equipment, Electrosurgical Devices And Equipment, Joint Reconstruction Devices And Equipment, Spinal Surgery Devices And Equipment, Trauma Fixation Devices And Equipment, Orthobiologics Devices And Equipment, Arthroscopy Devices And Equipment, Orthopedic Braces And Support Devices And Equipment, Craniomaxillofacial (CMF) Devices And Equipment, Orthopedic Prosthetics, Orthopedic Accessories,, Fetal And Neonatal Monitoring Devices, Weight Monitoring And Body Temperature Monitoring Devices And Equipment, Vital Parameter Monitoring Devices And Equipment, Remote Patient Monitoring Devices And Equipment, Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters, Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment, Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints, Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables, Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices, Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices The global medical equipment market grew from $639.75 billion in 2022 to $695.05 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global medical equipment is expected to grow to $922.39 billion in 2027 at a CAGR of 7.3%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. This is increasing the demand for medical devices used in the diagnosis, prognosis, and treatment of several diseases, thereby driving the demand for medical equipment. These factors are expected to increase the patient pool globally, thereby driving the growth of the medical equipment market during the forecast period. Major companies in the medical equipment market include Medtronic Inc., Abbott Laboratories, Johnson & Johnson, Cardinal Health, Inc., Becton Dickinson, Siemens AG, STRYKER CORPORATION, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., and Boston Scientific Corporation. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to cookieyed data 2021, in the US, PwC reported that 68% of 200 businesses surveyed intended to spend between $1 million and $10 million to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the medical equipment market. Device performance and patient data are available to healthcare service providers and are helping them to improve patient monitoring and overall care quality. Some companies are integrating medical equipment market data with EMR (Electronic Medical Records) to improve transparency and collaboration. As consumer wearables are becoming more common, patient data volumes are increasing and companies are investing in deploying data management, warehousing, and security technologies. For example, Medtronic launched a tool to augment their cardiac devices to securely transfer device data to doctors and allow them to monitor the critical health indicators of their patients. North America was the largest region in the global medical equipment market in 2022. Asia-Pacific was the second largest region in the global medical equipment market share. The regions covered in the medical equipment market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical equipment market consists of sales of devices used in the diagnosis, treatment and monitoring of medical conditions. The market includes diagnostic devices, imaging devices, surgical devices and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in the medical equipment market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified medical equipment market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the medical equipment market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The medical equipment market research report is one of a series of new reports from The Business Research Company that provides medical equipment market statistics, including medical equipment industry global medical equipment market size, regional shares, competitors with a medical equipment market share, detailed medical equipment market segments, medical equipment market trends and opportunities, and any further data you may need to thrive in the medical equipment industry. This medical equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Multivitamin capsules and tablets refers to multivitamin drugs that are used to treat or prevent vitamin deficiencies brought on by a poor diet, specific diseases, or pregnancy. Vitamins are crucial for maintaining your health because they serve as the body's building blocks. Multivitamins tablets and capsules are a combination of many different vitamins that are normally found in foods and other natural sources The main types of products include multivitamins tablets and multivitamins capsules. A multivitamin is a pill that people take every day which contains a variety of vitamins and minerals. The different distribution channels include store-based, non-store-based and are used for energy and weight management, general health, bone, and joint health, gastrointestinal health, immunity, cardiac health, diabetes, anti-cancer, and other applications. These capsules and tablets are mainly used by adults, the geriatric population, pregnant women, children, and infants. The global multivitamin capsules and tablets market is segmented - 1) By Type: Multivitamins Tablets, Multivitamins Capsules 2) By Distribution Channel: Store Based, Non-Store Based 3) By Application: Energy & Weight Management, General Health, Bone & Joint Health, Gastrointestinal Health, Immunity, Cardiac Health, Diabetes, Anti-Cancer, Other Applications 4) By End User: Adults, Geriatric, Pregnant Women, Children, Infants The global multivitamin capsules and tablets market size will grow from $20.28 billion in 2022 to $22.38 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the multivitamin capsules and tablets is expected to grow to $33.05 billion in 2027 at a CAGR of 10.2%. Increasing health consciousness among individuals is driving the market for multivitamin capsules and tablets. Multivitamins tablets or capsules are often prescribed by doctors to treat or prevent vitamin deficiency due to poor diet, certain illnesses, or during pregnancy as it contains different vitamins that are normally found in foods and other natural sources. The demand for multivitamins also increased attributing to rising health concerns associated with the COVID-19 pandemic. According to SVC Labs Ltd., a UK-based supplement manufacturer the sales for vitamins, minerals and supplements have increased since the beginning of March 2020 as people are concerned with boosting immune health. The sales of vitamins, minerals, and supplements have experienced growth of approximately 20%-140% since March 2020. Therefore, rising health consciousness is expected to drive the growth of multivitamin capsules and tablets market during the forecast period. Major players in the multivitamin capsules and tablets market are Herbalife Nutrition, Abbott Laboratories, Bayer, Nature's Bounty Co., Bionova Lifesciences, Ayanda GmbH, NutraMarks Inc., American Health Inc., Otsuka Holdings Co. Ltd., Nature's Way Products, Glanbia PLC., Pfizer, Mylan N.V., and Dymatize. Shifting consumer focus towards flavored gummy vitamins for all ages is shaping the multivitamin capsules and tablets market. Consumers are searching for more convenient and entertaining supplement experiences, which will lead to a move toward flavored gummy vitamins. For instance, in April 2021, Persona Nutrition, a US-based company that provides personalized daily supplement packs launched daily gummy vitamin packs for the entire family. These daily packs are designed to help users achieve specific health goals, such as immune health, focus, relaxation, everyday support, and hair, skin, and nail health. This family pack includes multivitamins to boost muscle and nerve function. In February 2021, Nature's Way Products, a US-based wellness product manufacturing company, acquired Baze Labs for an undisclosed amount. Through this acquisition, Nature's Way increases its personalized nutrition product capabilities for its customers, home blood test services, and monthly subscription programs. Baze Labs is a US-based personalized nutrition manufacturing company specializing in the development of vitamins and supplements. Asia-Pacific was the largest region in the multivitamin capsules and tablets market in 2022. North America was the second-largest market in the multivitamin capsules and tablets market. The regions covered in multivitamin capsules and tablets market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the multivitamin capsules and tablets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The multivitamin capsules and tablets market consists of sales of antioxidant capsule, iron folic acid tablet, multivitamin gummy, and nicotinamide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The multivitamin capsules and tablets market research report is one of a series of new reports from The Business Research Company that provides multivitamin capsules and tablets market statistics, including multivitamin capsules and tablets industry global market size, regional shares, competitors with a multivitamin capsules and tablets market share, detailed multivitamin capsules and tablets market segments, market trends and opportunities, and any further data you may need to thrive in the multivitamin capsules and tablets industry. This multivitamin capsules and tablets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastrointestinal (GI) bleeding is a sign of an illness in which the gastrointestinal system bleeds. The bleeding could occur anywhere in the gastrointestinal system, including the large intestine, anus, esophagus, small intestine, rectum, and stomach. The main type of products used in gastrointestinal bleeding treatment devices market are endoscopic mechanical devices, endoscopic thermal devices, and others. Endoscopic mechanical devices are used in the management of GI arterial bleeding. These include hemostatic clips, also known as through-the-scope (TTS) clips, endoscopic detachable snare ligation (EDSL) devices, endoscopic suturing, and over-the-scope clips (OTSC), and will be reviewed for their technology use and clinical application. The gastrointestinal bleeding treatment devices market is also segmented by GI tract division into the lower GI tract and upper GI tract and is used in hospitals or clinics, ambulatory surgical centers, others. The global gastrointestinal bleeding treatment devices market is segmented - 1) By Product: Endoscopic Thermal Devices, Other Products 2) By GI Tract Division: Upper GI Tract, Lower GI Tract 3) By End User: Hospitals Or Clinics, Ambulatory Surgical Centers, Other End-users The global gastrointestinal bleeding treatment devices market size grew from $0.78 billion in 2022 to $0.83 billion in 2023 at a compound annual growth rate (CAGR) of 6.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The gastrointestinal bleeding treatment devices market size is expected to grow to $1.03 billion in 2027 at a CAGR of 5.6%. The rise in the incidences of upper gastrointestinal bleeding is likely to contribute to the growth of the gastrointestinal bleeding treatment devices market during the forecast period. The upper gastrointestinal (GI) bleeding occurs in the esophagus, the stomach, or the upper part of the small intestine and can be caused due to peptic ulcers, esophagitis, enteritis, gastritis, cancer, and other reasons. For instance, according to the National Institute for Health and Care Excellence, in the UK the incidence of acute upper GI bleeding ranges from 84-172 per 100,000 of the population per year. Furthermore, as per the study published by the International Journal of Surgery Global Health in May 2020, the incidence of acute upper GI bleeding in the Western world recorded to be 103 cases per 100,000 adults annually. Therefore, the rise in the incidences of upper gastrointestinal bleeding propels the growth of the gastrointestinal bleeding treatment devices market. Major players in the gastrointestinal bleeding treatment devices market are CONMED, Boston Scientific Corporation, US Medical Innovations, Ovesco Endoscopy AG, Olympus Corporation, Cook Medical, Erbe Elektromedizin GmbH, Steris PLC, and Pfizer Inc. The increasing number of product approvals is the key trend gaining popularity in the gastrointestinal bleeding treatment devices market. Key players in the market are focusing on product approvals to maintain a comparative advantage over competitors in the industry. For example, in February 2021, EndoClot Plus Inc., a US-based company developing medical devices to meet the needs of the GI professional announced U.S. Food and Drug Administration (FDA) approval for EndoClot Polysaccharide Hemostatic System (EndoClot PHS), which is an advanced product that will assist Gastroenterologists to stop bleeding quickly and effectively. EndoClot PHS is a one-time-use device that consists of a starch-based powder hemostat that is applied directly to the bleeding location using a flexible endoscope. In January 2021, Olympus Corporation, a Japan-based company offering solutions for the effective treatment of gastrointestinal bleeding, announced a collaboration with Hitachi Ltd for five-year. Under this collaboration, the companies will work together to develop Endoscopic Ultrasound Systems (EUS), which are used to treat digestive diseases and assess the stage of cancer in the bronchus, liver, pancreas as well as in minimally invasive care, thereby contributing to medical treatment. Hitachi Ltd is a Japanese multinational conglomerate company offering gastrointestinal diagnoses solutions. North America was the largest region in the gastrointestinal bleeding treatment devices market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal bleeding treatment market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the gastrointestinal bleeding treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The gastrointestinal bleeding treatment devices market consists of sales of thermal therapy, multipolar electrocoagulation probe, heater probe, hemostatic foreceps, and argon plasma coagulation. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The gastrointestinal bleeding treatment market research report is one of a series of new reports from The Business Research Company that provides gastrointestinal bleeding treatment market statistics, including gastrointestinal bleeding treatment industry global market size, regional shares, competitors with a gastrointestinal bleeding treatment market share, detailed gastrointestinal bleeding treatment market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal bleeding treatment industry. This gastrointestinal bleeding treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal diseases drug categories include Anti-peptic agents (antacids, antagonists, Proton Pump Inhibitors, Sucralfate, and Misoprostol), antiemetics, adsorbents, anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants, hyperosmotic, saline, and simulant/irritant. The main types of gastrointestinal drugs are antacids, antiulcerants, vitamin and minerals, antiobesity, antiemetics and antinauseants and antidiarrhoeals. Antacids are medications that counteract (neutralise) stomach acid to relieve indigestion and heartburn. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global gastrointestinal drugs market size is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%. The change in the gastrointestinal drugs market growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The gastrointestinal drugs market is expected to reach $105.51 billion in 2026 at a CAGR of 8.7%. The aging population profile of most countries will contribute to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, will contribute significantly to the growth of the market during the forecast period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This will led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. During the forecast period, the growth of the gastrointestinal drugs market will be restrained by patent expiration of branded gastrointestinal drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this will negatively impact the growth of the market in terms of value. Major companies in the gastrointestinal drug industry are investing in making oral capsules of macromolecular drugs for gastrointestinal diseases for making the drug more effective. Macromolecular drugs, such as peptides, proteins, and antibodies, form a new class of drugs which can treat diseases of the gastrointestinal tract, such as inflammatory bowel disease. These macromolecular drugs are usually injected and only a fraction of the administered dose reaches the disease sites in the gastrointestinal tract. Thus, major companies such as Eli Lilly have been increasingly investing in making oral capsules for macromolecular drugs. The company invested $5 million to enter into a collaboration with Entrega to study the oral delivery of complex molecules, such as peptides to combat gastrointestinal diseases. Major companies in the gastrointestinal drugs market include Takeda Pharmaceuticals, Bayer AG, Abbott Laboratories, Otsuka Holdings Co ltd, Johnson & Johnson, Reckitt Benckiser Group plc, Bausch Health Companies Inc., Sanofi S.A, Procter & Gamble and Daiichi Sankyo Company. North America was the largest region in the gastrointestinal drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the gastrointestinal drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastrointestinal drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global gastrointestinal drugs market is segmented - 1) By Type: Antacids, Antiulcerants, Vitamin and Minerals, Antiobesity, Antiemetics and Antinauseants, Antidiarrhoeals 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs